318 related articles for article (PubMed ID: 31418878)
21. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
22. High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
DeAtkine AB; Abdelrashid M; Tucker Z; Mehta A; Markert JM; Kim J; Fiveash JB; Oster RA; Lobbous M; Nabors LB
J Neurooncol; 2022 May; 158(1):33-40. PubMed ID: 35441948
[TBL] [Abstract][Full Text] [Related]
23. Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma.
Zhao HT; Chen J; Shi SB; Tian J; Tao RJ
Med Oncol; 2015 Jan; 32(1):351. PubMed ID: 25428379
[TBL] [Abstract][Full Text] [Related]
24. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM
Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418
[TBL] [Abstract][Full Text] [Related]
25. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
Schorb E; Fox CP; Kasenda B; Linton K; Martinez-Calle N; Calimeri T; Ninkovic S; Eyre TA; Cummin T; Smith J; Yallop D; De Marco B; Krampera M; Trefz S; Orsucci L; Fabbri A; Illerhaus G; Cwynarski K; Ferreri AJM
Br J Haematol; 2020 Jun; 189(5):879-887. PubMed ID: 31997308
[TBL] [Abstract][Full Text] [Related]
26. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.
Ghose A; Elias HK; Guha G; Yellu M; Kundu R; Latif T
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):451-7. PubMed ID: 25816933
[TBL] [Abstract][Full Text] [Related]
27. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis.
Epperla N; Hamadani M; Reljic T; Kharfan-Dabaja MA; Savani BN; Kumar A
Cancer; 2019 Dec; 125(24):4417-4425. PubMed ID: 31441943
[TBL] [Abstract][Full Text] [Related]
28. Review of rituximab in primary CNS lymphoma.
Singh PK; Pan E
J Neurol Sci; 2020 Mar; 410():116649. PubMed ID: 31901591
[TBL] [Abstract][Full Text] [Related]
29. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
Moccia AA; Zucca E; Ghielmini M
Leuk Lymphoma; 2017 Jan; 58(1):30-36. PubMed ID: 27813427
[TBL] [Abstract][Full Text] [Related]
30. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
31. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
[TBL] [Abstract][Full Text] [Related]
32. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
33. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
[TBL] [Abstract][Full Text] [Related]
34. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G
Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800
[TBL] [Abstract][Full Text] [Related]
35. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
36. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis.
Liu PP; Wang KF; Jin JT; Bi XW; Sun P; Wang Y; Yang H; Li ZM; Jiang WQ; Xia Y
Cancer Med; 2018 May; 7(5):1845-1851. PubMed ID: 29624913
[TBL] [Abstract][Full Text] [Related]
37. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
[TBL] [Abstract][Full Text] [Related]
38. Upfront autologous stem cell transplantation for untreated diffuse large B cell lymphoma patients in rituximab era: a systematic review and meta-analysis.
Ma SY; Tian XP; Cai J; Zhong GZ; Chen X; Huang HQ; Lin TY; Li ZM; Cai QQ
Ann Hematol; 2020 Jun; 99(6):1311-1319. PubMed ID: 32285160
[TBL] [Abstract][Full Text] [Related]
39. Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
Faivre G; Butler MJ; Le I; Brenner A
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):665-669. PubMed ID: 31351990
[TBL] [Abstract][Full Text] [Related]
40. The Role of Rituximab in Primary Central Nervous System Lymphoma.
Bromberg JEC; van der Meulen M; Doorduijn JK
Curr Oncol Rep; 2020 Jun; 22(8):78. PubMed ID: 32602069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
